394734-96-4

Upstream product

• 60-29-7 diethyl ether 
• 64416-07-5 (4,4-dimethylcyclohexylidene)methyl methyl ether 
• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 849671-56-3 spiro[2.5]octan-6-ylmethanol 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 145576-28-9 ethyl 4-methylidenecyclohexanecarboxylate 
• 1073-13-8 4,4-dimethylcyclohexenone 

Downstream Products

• 1007578-76-8 [(4,4-dimethylcyclohexyl)methyl](phenylmethyl)amine 
• 140423-42-3 1,4,4-trimethylcyclohexanecarbaldehyde 
• 1210879-13-2 C₁₁H₂₂O 
• 1007578-77-9 [(4,4-dimethylcyclohexyl)methyl]amine hydrochloride 

Relevant academic research and scientific papers

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

OXYSTEROLS AND METHODS OF USE THEREOF

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

COMPOSITIONS AND METHODS FOR MODULATING FXR

The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE

Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.

Novel peptides as NS3-serine protease inhibitors of hepatitis C virus

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.